In the past 60 days, estimates for Voyager Therapeutics’ loss per share have narrowed from $1.72 to $1.48 for 2025. In the past year, shares of VYGR have plunged 32.8%. VYGR’s earnings beat ...

The U.S. Food and Drug Administration (FDA) has approved Amgen’s (NASDAQ:AMGN) KRAS G12C inhibitor Lumakras as part of a ...

Amgen's pathfinder KRAS inhibitor Lumakras has been shown to be effective in KRAS-mutated non-small cell lung cancer (NSCLC) in a phase 3 trial that should serve as a confirmation study for its ...

Two weeks after Amgen reported the top-line result of its CodeBreak-200 trial of Lumakras in lung cancer, the data has been presented in abstract form at ESMO, showing a 34% improvement in ...

Tied with Cabenuva for second place was Amgen’s Lumakras, which was approved in 2021 for non-small cell lung cancer and boasted impressive therapeutic and R&D scores, but fell behind both ...

Now two KRAS inhibitors, Amgen’s sotorasib (Lumakras) and BMS/Mirati’s adagrasib (Krazati), are approved — and many more are in the clinic. But while clinicians had high hopes that these ...